⬡ THIRD-PARTY HPLC TESTED⬡ >98% PURITY GUARANTEED⬡ CERTIFICATE OF ANALYSIS INCLUDED⬡ PREMIUM GRADE COMPOUNDS⬡ FAST TRACKED SHIPPING⬡ 100+ PREMIUM PEPTIDES⬡ THIRD-PARTY HPLC TESTED⬡ >98% PURITY GUARANTEED⬡ CERTIFICATE OF ANALYSIS INCLUDED⬡ PREMIUM GRADE COMPOUNDS⬡ FAST TRACKED SHIPPING⬡ 100+ PREMIUM PEPTIDES⬡ THIRD-PARTY HPLC TESTED⬡ >98% PURITY GUARANTEED⬡ CERTIFICATE OF ANALYSIS INCLUDED⬡ PREMIUM GRADE COMPOUNDS⬡ FAST TRACKED SHIPPING⬡ 100+ PREMIUM PEPTIDES⬡ THIRD-PARTY HPLC TESTED⬡ >98% PURITY GUARANTEED⬡ CERTIFICATE OF ANALYSIS INCLUDED⬡ PREMIUM GRADE COMPOUNDS⬡ FAST TRACKED SHIPPING⬡ 100+ PREMIUM PEPTIDES

BPC-157 Complete Healing Protocol

A pentadecapeptide of 15 amino acids naturally found in human gastric juice. BPC-157 is the most studied healing peptide in published literature — with 120+ peer-reviewed studies documenting its effect on tendon, gut, muscle, and neural repair through distinct, validated molecular pathways.

Below: complete injection protocol, healing timeline by tissue type, mechanism of action, BPC-157 vs TB-500 comparison, and dosing guide based on published research.

For laboratory and research use only. Not for human consumption.

Why BPC-157 Is the Benchmark Healing Peptide

No other healing peptide has the published breadth of BPC-157. Its evidence base spans multiple tissue types, multiple species, and multiple research groups — independently replicated findings across decades.

120+
Published Studies
More peer-reviewed publications than any other healing peptide. Research spans tendon, gut, muscle, bone, neural, and cardiac tissue across multiple independent groups.
15
Amino Acids
BPC-157 is a pentadecapeptide — 15 amino acids — derived from the BPC (Body Protection Compound) sequence found in human gastric juice. Synthetic form identical to the endogenous sequence.
5
Tissue Types Validated
Tendon, ligament, gut mucosa, muscle, and neural tissue — all with published mechanistic studies in peer-reviewed journals. No other single peptide spans this breadth of documented healing targets.
7 days
Tendon Healing Onset
Measurable tendon fibroblast outgrowth and FAK/paxillin upregulation documented within 7 days of administration in transected Achilles tendon models — the fastest documented healing induction in this tissue.

What BPC-157 Heals

Each of the following has mechanistic and outcome data in peer-reviewed literature. BPC-157 does not operate via a single pathway — it recruits distinct signaling cascades depending on the tissue type.

Tendon & Ligament

Fastest tendon healing ever documented in animal models

BPC-157 upregulates FAK (focal adhesion kinase) and paxillin signaling in tendon fibroblasts — the specific pathway responsible for extracellular matrix remodeling and collagen fiber realignment. Studies demonstrate measurable tendon-to-bone healing acceleration within 7 days that exceeds all other known peptide interventions. Tendon fibroblast proliferation and outgrowth are dramatically enhanced even under conditions of mechanical disruption.

Brcic et al. (2018). J Orthop Res — Tendon healing in transected Achilles tendon model.

Gut & GI Tract

Systemic GI repair: leaky gut, IBD, gastric ulcers, NSAID damage

BPC-157 is naturally found in gastric juice at low concentrations — it was first isolated from the human stomach. Its cytoprotective effect on the GI mucosa is well-documented across models of gastric ulcer, NSAID-induced enteropathy, and inflammatory bowel disease. It restores tight junction protein expression (occludin, ZO-1) that defines gut permeability, reduces gut wall inflammation via NF-κB downregulation, and reverses mucosal atrophy. Oral administration is uniquely effective for GI targeting — the peptide is acid-stable at gastric pH.

Sikiric et al. (2018). Curr Pharm Des — BPC-157 cytoprotection in GI tract models.

Muscle

Satellite cell activation and accelerated muscle fiber repair

In muscle crush and laceration models, BPC-157 significantly accelerates functional recovery through satellite cell (muscle stem cell) activation, angiogenesis at the wound site via VEGF upregulation, and anti-inflammatory remodeling of damaged fiber architecture. Nitric oxide pathway activation increases blood flow to injured tissue, delivering oxygen and substrates essential for repair. Myotendinous junction injuries — notorious for their poor healing prognosis — show particularly notable response.

Chang et al. (2011). Regul Pept — Muscle fiber repair and satellite cell activation model.

Neurological

Motor neuron repair, neuroprotection, and crush injury recovery

BPC-157 demonstrates neuroprotective properties that extend beyond peripheral tissue. In sciatic nerve crush injury models, it significantly accelerates functional motor recovery — an outcome few compounds achieve in neuroscience. It promotes neurite outgrowth, protects against dopaminergic lesion-induced neurodegeneration, and has shown anti-seizure activity in CNS models. The nitric oxide pathway is again central: NO modulation in neural tissue affects both inflammation and neural plasticity.

Sikiric et al. (2014). CNS Neurosci Ther — BPC-157 neuroprotection and crush injury models.

BPC-157 Healing Week-by-Week Timeline

What is happening biologically versus what researchers and subjects observe — based on published mechanistic data from multiple injury models. Tendon and gut timelines are the most thoroughly documented.

1
Week 1–2Acute Response
What's Happening
Nitric oxide pathway activation begins immediately — increasing local blood flow and oxygen delivery to injured tissue. VEGF (vascular endothelial growth factor) upregulation initiates angiogenesis: new capillary formation begins at the injury site within 48–72 hours of first administration.
What You May Notice
Reduction in acute inflammation at the injury site. Pain and swelling begin to decrease faster than unassisted healing. Range of motion begins returning to joints. GI users typically notice gut discomfort improving within the first week.
Clinical Context
FAK/paxillin signaling in tendon fibroblasts is measurably elevated in the first 7 days — the mechanistic driver of the rapid early tendon healing effect seen in animal studies.
The early anti-inflammatory effect is not simple pain masking — it reflects genuine downstream modulation of inflammatory cascade signaling at the wound site.
2
Week 3–4Active Tissue Repair
What's Happening
Collagen synthesis in tendon and connective tissue is meaningfully elevated. Fibroblast proliferation is in full swing — new extracellular matrix is being laid down. In muscle models, satellite cell activation and myofiber regeneration are at peak activity during this window.
What You May Notice
Tendon and ligament injuries: returning functional strength. Active tissue feel — the area of injury begins to feel less fragile. Gut healing subjects: significant improvement in digestive comfort, stool regularity, and mucosal sensitivity.
Clinical Context
The VEGF-driven angiogenesis initiated in weeks 1–2 is now producing a functional new vascular network at the injury site — this is the structural basis for accelerated tissue oxygenation that underpins the healing speed advantage.
This is the window where local injection protocols (injecting near the injury site) show the greatest advantage over systemic protocols — localized VEGF and fibroblast signaling is highest here.
3
Week 6–8Remodeling
What's Happening
Collagen fiber remodeling and alignment. New collagen laid down in weeks 3–4 begins undergoing organizational remodeling — fibers align along lines of mechanical stress, increasing tensile strength. The tissue transitions from scar-like repair toward functional tissue architecture.
What You May Notice
Tendon/ligament: returning to load-bearing activity. Strength approaching pre-injury baseline. Muscle: functional strength recovery largely complete. Neural: progressive motor function return in nerve injury protocols.
Clinical Context
At the 6-week mark in published tendon models, BPC-157-treated tissue demonstrates superior collagen fiber organization and tensile strength compared to controls — not just faster healing, but better quality repair.
For chronic injuries (tendinopathies that have been present for months or years), the 6–8 week window may correspond to the first meaningful tissue-level change rather than full recovery.
4
Week 12+Consolidation
What's Happening
Tissue consolidation, maturation of collagen matrix, and normalization of tissue architecture. In neurological recovery protocols, continued progressive improvement in motor function as axonal regrowth and remyelination proceed. GI mucosal integrity is fully restored.
What You May Notice
Full or near-full return to pre-injury functional capacity for most injury types. For severe injuries or surgical recovery protocols, this marks the window of return to full training or competitive activity.
Clinical Context
Full 12-week cycles are recommended for severe injuries, surgical recovery, or chronic tendinopathies. Mild-to-moderate acute injuries often complete their primary healing response by weeks 6–8, allowing dose reduction or discontinuation.
Cycle lengths of 4–6 weeks are appropriate for minor injuries. 8–12 weeks for moderate-to-severe injuries or post-surgical repair. Continuous use beyond 12 weeks is not validated in published models.

BPC-157 Dosing Protocol

Two primary protocols used in research contexts — systemic subcutaneous and local injection near the injury site. Both are documented in published literature. Protocol choice depends on the primary healing target.

Systemic Protocol
Dose
250–500 mcg
Frequency
Daily
Route
Subcutaneous injection
Injection Site
Belly fat (umbilical region)
Cycle Length
4–12 weeks
Best For

Gut healing, general recovery, neurological protocols, systemic anti-inflammatory effect

Lower 250 mcg dose for gut-focused protocols and first-time users. 500 mcg for active injury recovery with higher healing demand.
Local Injection Protocol
Dose
250 mcg
Frequency
Daily
Route
Subcutaneous near injury site
Injection Site
Subcutaneous fat adjacent to injury
Cycle Length
4–8 weeks
Best For

Tendon, ligament, and muscle injuries — maximum local tissue concentration

Inject into the subcutaneous layer as close to the injury site as safely possible. Do not inject directly into tendon tissue. Local delivery maximizes fibroblast signaling at the site of injury.
Cycle Length by Injury Severity
Injury TypeSeverityRecommended CycleNotes
Acute tendon/ligamentMinor sprain/strain4–6 weeksCan discontinue when pain-free under load
Muscle tearModerate6–8 weeksLocal injection preferred in first 2 weeks
Tendon/ligamentSevere (partial tear)8–12 weeksFull cycle recommended; consider stacking TB-500
Post-surgical recoverySurgical repair12 weeksBegin as early as possible post-surgery; full cycle
Chronic tendinopathyChronic/longstanding10–12 weeksAllow extended time for collagen remodeling in chronic tissue
Gut/GI healingLeaky gut / IBD6–12 weeksOral administration; dose on low end (250 mcg)

Injection Sites &
Administration Guide

BPC-157 is administered subcutaneously (SC) as the primary route in most published research protocols. The injection site selection depends on whether you are running a systemic protocol (general healing, gut, neural) or a local protocol (specific injury site targeting).

Intramuscular (IM) injection is used in some muscle-focused protocols and is documented in published models. For GI healing, oral administration dissolved in water is uniquely effective given BPC-157's acid stability — oral bioavailability for gut mucosa exposure is considered valid and is the preferred route for GI-specific protocols.

Reconstitution: Reconstitute lyophilized BPC-157 powder with bacteriostatic water. Standard reconstitution for a 10mg vial: add 2 mL bacteriostatic water = 5,000 mcg/mL. Draw 0.05 mL for 250 mcg dose. Store reconstituted peptide refrigerated; use within 30 days.
Subcutaneous — Periumbilical (Belly Fat)Most Common
Systemic protocol
Pinch belly fat in the umbilical region. Insert 29–31g insulin syringe at 45°. Inject slowly. This is the standard systemic injection site — provides reliable absorption into circulation for systemic healing protocols, gut healing, and neurological protocols.
Subcutaneous — Near Injury SiteLocal Protocol
Local protocol
Inject into subcutaneous fat tissue as close to the injury as possible. For Achilles tendon: inject into fat pad adjacent to the heel. For knee: inject into subcutaneous fat around the knee. Do not inject directly into tendon tissue. Local delivery maximizes fibroblast signaling concentration at the site.
Intramuscular (IM)Deep Tissue
Muscle protocols, deep tissue
Inject into the belly of a large muscle (quad, glute, deltoid). Used in muscle repair protocols and when deep tissue penetration is desired. 27–29g needle recommended. IM delivery produces a depot effect — slower, sustained release over several hours.
Oral (dissolved in water)GI Protocol
GI healing protocols only
Dissolve the dose in a small amount (5–10 mL) of sterile water. Swallow on an empty stomach. BPC-157 is stable at gastric pH — unlike most peptides, it is not degraded by stomach acid, making oral delivery genuinely effective for GI mucosal exposure. Not recommended as primary route for systemic or tendon protocols.

How BPC-157 Works

BPC-157 recruits multiple molecular pathways simultaneously — which explains why it works across so many different tissue types. Its effect is not reducible to a single mechanism.

Nitric Oxide (NO) PathwayUpregulated
BPC-157 is a potent nitric oxide system modulator. It acts as an eNOS activator — increasing endothelial nitric oxide production which drives vasodilation, increased blood flow, and oxygen delivery to injured tissue. The NO pathway also mediates its neuroprotective and gut-protective effects.
VEGF UpregulationUpregulated
Vascular endothelial growth factor (VEGF) drives angiogenesis — the formation of new blood vessels. BPC-157 significantly upregulates VEGF expression, producing new capillary networks in damaged tissue within the first 72 hours of administration. This vascular restoration is the structural basis for accelerated tissue repair.
FAK / Paxillin SignalingActivated
Focal adhesion kinase (FAK) and paxillin are the central signaling nodes for tendon fibroblast behavior — governing cell migration, proliferation, and extracellular matrix production. BPC-157 dramatically upregulates FAK/paxillin activity in tendon fibroblasts, which is the primary mechanism behind its industry-leading tendon healing speed.
Growth Hormone ReceptorUpregulated
BPC-157 upregulates growth hormone receptor expression — sensitizing tissues to endogenous GH and IGF-1 signaling. This amplifies the anabolic and regenerative signaling environment without directly raising GH levels, explaining its efficacy in muscle and bone repair contexts.
NF-κB Inflammatory PathwayDownregulated
Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) is the master regulator of inflammatory gene expression. BPC-157 downregulates NF-κB activity — reducing production of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) that drive chronic inflammation and impede tissue repair.

BPC-157 vs TB-500 — When to Use Which

BPC-157 and TB-500 (Thymosin Beta-4 fragment) are the two most frequently stacked healing peptides. They operate via entirely different molecular mechanisms and have distinct tissue preferences — making them highly complementary. Understanding when to use each, and when to stack both, is essential for an effective healing protocol.

FeatureBPC-157TB-500
Primary mechanismFAK/paxillin, NO pathway, VEGFActin regulation (Thymosin β4), systemic repair
Published studies120+ studies50+ studies
Half-lifeShort (hours) — requires daily dosingModerate (days) — 2x/week sufficient
Best injury typeTendon, gut, neural, local tissueMuscle, systemic, widespread injury
AdministrationOral (gut), subQ, or IMSubQ or IM only
Standard dose250–500 mcg/day2–5 mg twice weekly
Gut healingYes — primary indicationLimited gut evidence
AngiogenesisStrong via VEGFModerate via thymosin mechanism
Neural repairYes — motor neuron studiesLimited neural evidence
Stack benefitLocal healing + gutSystemic + muscle sweep

Use BPC-157 Alone When

Primary target is gut or GI healing (oral BPC is uniquely effective)
Localized tendon or ligament injury in a single site
Neurological recovery protocol (crush injury, neuropathy)
Budget constraints — BPC-157 is typically lower cost
First peptide healing protocol (simpler single-compound approach)

Use TB-500 Alone When

Widespread muscle soreness or systemic recovery demand
Injuries distributed across multiple body areas simultaneously
Longer dosing intervals are preferred (2x/week vs daily)
Athlete general recovery — broad systemic anti-inflammatory effect
No gut pathology — TB-500 lacks meaningful GI targeting

Stack Both — The Wolverine Protocol

Severe acute injury: tendon, ligament, or combined injury
Post-surgical recovery for fastest possible tissue healing
Chronic tendinopathy with systemic inflammatory component
High-volume athletic contexts with multiple concurrent stressors
BPC-157 handles local repair; TB-500 handles systemic sweep

BPC-157 10mg — Research Grade

Third-party HPLC tested. Greater than 98% purity. Full Certificate of Analysis. The reference standard for healing peptide research protocols — tendon, gut, muscle, and neural.

Lyophilized powder — stable at room temperature
Sterile vial, ready for reconstitution with bacteriostatic water
Certificate of Analysis on every batch
For laboratory and research use only. Not for human consumption.

BPC-157 — The Most Studied Healing Peptide

Verified purity. Certificate of Analysis on every order. The reference compound for tendon, gut, muscle, and neural repair research protocols.